| Similar Articles |
 |
The Motley Fool March 28, 2008 Brian Lawler |
Vertex Tantalizes Us With Very Early Data Vertex announces positive early-stage data for a cystic fibrosis drug.  |
Chemistry World June 9, 2015 Phillip Broadwith |
Vertex nabs rights to cystic fibrosis molecules Specialist pharmaceutical firm Vertex has struck a development deal with start-up Parion Sciences to develop Parion's investigational drug candidates for respiratory diseases, including cystic fibrosis.  |
Fast Company November 1, 2007 Tinker Ready |
Drug Flow and Deal Flow The news at this year's Biotech Investing confab will focus on Big Pharma companies, as they take a more active role in developing early-stage drugs.  |
The Motley Fool July 21, 2010 Ryan McBride |
Eli Lilly Pays up to $380M for Alnara Pharma Indianapolis-based Lilly is paying $180 million upfront for all of Alnara's shares, and shareholders are eligible for as much as $200 million in additional payments depending on whether certain regulatory and commercial milestones are met.  |
Chemistry World September 7, 2015 |
Cancer Drugs Fund axes 23 treatments The Cancer Drugs Fund, which covers the cost of some cancer treatments that are not currently available on the National Health Service, has cut 23 treatments -- involving 16 drugs.  |
The Motley Fool July 27, 2004 Charly Travers |
Cash Concerns at Vertex New royalties might not help offset losses at the pharmaceutical, so it's time to look at the drug pipeline.  |
Pharmaceutical Executive April 1, 2011 |
Winning Beyond the Molecule It can take both a clinical and non-clinical approach to win the differentiation competition.  |
The Motley Fool June 29, 2009 Brian Orelli |
Funding From an Unlikely Place Nonprofits still have money, and they seem willing to fork it over to for-profit drug companies.  |
The Motley Fool July 22, 2011 Brian Orelli |
That's All the Melanoma Market Is Worth? BioSante licenses out its melanoma vaccine for $100,000.  |
The Motley Fool June 9, 2011 Brian Orelli |
It's a Numbers Game With Vertex In the longer term, the number of patients Vertex can address with its cystic fibrosis drugs will play a major role in its valuation.  |
The Motley Fool April 23, 2008 Brian Lawler |
Vertex Verging on Crucial News Soon-to-arrive study results could decide the future of Vertex Pharmaceutical's lead drug telaprevir.  |
The Motley Fool August 4, 2010 Ryan McBride |
How Eli Lilly Let a Billion-Dollar Molecule Slip Away, and Make a Fortune for Vertex The remains of Lilly's partnership with Vertex Pharmaceuticals.  |
The Motley Fool October 28, 2011 Brian Orelli |
Invest in Biotechs Going After Unmet Needs What a quarter it was for Vertex Pharmaceuticals: $420 million in net sales of its new hepatitis C drug.  |
AFP eWire April 9, 2007 |
Foundation Giving Rises to $40 Million Foundation giving in the United States grew to $40.7 billion in 2006, an 11.7% increase from the previous year, according to a new study.  |
The Motley Fool March 27, 2007 |
Fast Pitch: Vertex Pharmaceuticals 2007 is expected to be a very eventful year for the pharmaceutical, as it will furnish some important clinical trial results for its investigational drugs. Investors, take note.  |
AFP eWire April 12, 2004 |
U.S. Foundation Giving Declines Slightly in 2003 Grantmaking foundations in the United States gave slightly less in 2003 campared to the previous year.  |
U.S. Banker June 2002 John Hackett |
Can't Go Wrong As more Americans set up private foundations, banks find that not only do they bring in money directly, they also attract other wealth management business.  |
The Motley Fool March 20, 2009 Brian Orelli |
EU to Gilead: More Trials for You The U.S. isn't ready for Gilead Sciences' new cystic fibrosis drug, and neither is Europe.  |
Managed Care June 2003 |
Effectiveness of review process in eye of beholder From January 1999 to December 2000, 263 independent medical reviews were conducted in California as a result of patients trying to overturn coverage decisions by health plans. The Institute of Medical Quality surveyed those patients to obtain their opinions on the review process.  |
AFP eWire April 24, 2006 |
Slow, Steady Foundation Growth Seen in 2005, Expected in 2006 A new report shows steady, but unremarkable growth for the foundation sector in 2005 and forecasts much of the same for 2006.  |
The Motley Fool September 8, 2010 Brian Orelli |
You Must Realize This Drug Works by Now Vertex concludes its phase 3 trials with another win.  |
The Motley Fool March 30, 2009 Brian Orelli |
Change the Game? Change the Rules! There are ways for investors to get around Obama's plan to lower health care costs. Investing in drug companies in this time of "change" doesn't have to be scary. You've just got to find rule breaker-type drugmakers, because playing by the rules isn't going to cut it anymore.  |
The Motley Fool September 9, 2004 Charly Travers |
The Case for Drug Stocks The reports of the drug industry's death are greatly exaggerated.  |
Inc. December 2006 Daniel Akst |
Foundations R Us You can give it away as smartly as you made it.  |
The Motley Fool June 9, 2011 Brian D. Pacampara |
Vertex Pharmaceuticals Shares Plunged: What You Need to Know Shares of drug developer Vertex Pharmaceuticals sank as much as 13% after reporting initial data on their combination cystic fibrosis treatment.  |
The Motley Fool March 31, 2011 Brian Orelli |
Hepatitis C Drugs Heat Up The current hepatitis C drugs stink. Who's ahead in the race to find new ones?  |
Chemistry World July 31, 2012 Andrew Turley |
New cystic fibrosis drug in EU Ivacaftor, which is marketed under the brand name Kalydeco, won US approval in January.  |
The Motley Fool October 31, 2011 Brian Orelli |
5 One-Drug Wonders Going for No. 2 Here are five drugmakers hoping not to become one-hit wonders: Vertex... Onyx... Momenta... Elan... Dendreon...  |
The Motley Fool August 4, 2008 Brian Lawler |
Vertex on the Verge of Victory Like the majority of biotech drugmakers, Vertex's financials proved less crucial in the second quarter than the clinical trial results from the drugmaker's pipeline.  |
Managed Care February 2004 Bob Carlson |
Finding Common Ground: Where Foundations, MC Meet Tapping into local foundations' expertise and knowledge is one way managed care can start to reinvent itself.  |
AFP eWire May 17, 2004 |
Report Reveals What Grantees Value in Foundations A new report from the Center for Effective Philanthropy has identified several key areas that charity grantees most value in the foundations that fund their programs.  |
AFP eWire May 19, 2008 |
Advice to Grant Seekers: Never Believe Your Own PR Grant seekers should remember to bring their data and a level head -- not a sales pitch -- when they approach a foundation for grant money.  |
HBS Working Knowledge June 28, 2010 Julia Hanna |
HBS Cases: Cincinnati Children's Hospital Medical Center This case explores how one hospital implemented its own version of health-care reform, taking overall performance levels from below average to the top 10 percent in the industry.  |
Foundation News & Commentary Sep/Oct 2006 Francie Ostrower |
Staying the Course A new study of community foundation effectiveness generates suggestions for increasing grantmaking impact.  |
The Motley Fool June 22, 2004 Charly Travers |
Merck Pays Up for a Cancer Drug As demonstrated this morning with the announcement of a major deal with Vertex Pharmaceuticals, Merck is now in the midst of a strategic push to build out its oncology pipeline.  |
Foundation News & Commentary Nov/Dec 2005 Simone & Venkat |
Planning for Consistency Corporate grantmakers can achieve stability through creating endowments, quasi-endowments and reserves. Here's how.  |
PC Magazine March 16, 2005 Cade Metz |
Your Request Is Granted We go inside the soup-to-nuts Web site for running charitable foundations online.  |
The Motley Fool November 3, 2008 Dan Caplinger |
Do Good Without Being a Corporate Hotshot Don't let modest means stop you from giving what you can to charity.  |
The Motley Fool July 29, 2011 Brian Orelli |
Vroom! There Goes Vertex Vertex Pharmaceuticals' Incivek launch is off to a good start.  |
The Motley Fool March 4, 2009 Brian Orelli |
Vertex Combines to Keep From Being Ground Up Vertex Pharmaceuticals announces that it is buying ViroChem Pharma, getting two early stage hepatitis C compounds in the deal.  |
The Motley Fool April 21, 2011 Brian Orelli |
Who's Next? 5 Potential Biotech Takeover Targets Exelixis has reportedly hired Goldman Sachs to shop the development-stage drugmaker around to the highest bidder. With an asset like XL184, there should be someone interested.  |
Foundation News & Commentary Mar/Apr 2006 |
Communications Par Excellence Here are the Council on Foundations' Wilmer Shields Rich Awards for Excellence in Communications program, which recognizes and encourages effective communications by foundations and corporate giving programs: Skoll Foundation... etc.  |
The Motley Fool October 19, 2007 Brian Lawler |
Schering's Gain Is Only a Mild Headache for Vertex Schering-Plough's strong phase 2 clinical results of its hepatitis C virus drug candidate send shares of competitor Vertex down.  |
The Motley Fool January 24, 2008 Brian Lawler |
Vertex Under the Gun Vertex announces development plans for its lead drug. Investors, take note.  |
Foundation News & Commentary Sep/Oct 2005 Freeland & Royal |
Perpetuating Community Philanthropy Here's how one foundation rose to the challenge of being more entrepreneurial and innovative to stimulate economic growth throughout the community.  |
Foundation News & Commentary Mar/Apr 2005 |
Celebrating Strategic Communications Here are the winners of the Council on Foundations' Wilmer Shields Rich Awards for Excellence in Communications. The awards recognize and encourage effective communications by foundations and corporate giving programs.  |
Financial Planning October 1, 2008 Jim Grote |
Foundations for Renown Assets in domestic private foundations are growing and donors are demanding more customized service from advisory firms.  |
The Motley Fool December 16, 2011 Brian Orelli |
Biotech Royalties, Almost as Good as Cash They're flexible, and all royalties have value.  |
Inc. May 1, 2002 Donna Fenn |
Shaking the Foundations Sanjay Chopra is an astute donor. The founder of two technology companies recently joined 59 other fledgling philanthropists to give $50,000 to KidsVoice, a Pittsburgh nonprofit that provides legal services to children in juvenile court...  |
The Motley Fool November 30, 2010 Dan Caplinger |
You Don't Have to Be Rich to Do Good Supporting charity isn't just for billionaires.  |